This CPB has been revised to state that bortezomib is considered experimental and investigational (i) as monotherapy or in combination with other chemotherapeutics for the treatment of biliary tract cancer, follicular lymphoma, and mucosa-associated lymphoid tissue (MALT) lymphoma, and (ii) for the treatment of Castleman's disease.